Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD11B1 | P28845 | 9/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16865194 | 0.85 | RET (0.34) | HSD11B1 | |
| SCHEMBL16838106 | 0.80 | HSD11B1 (0.44) | HSD11B1 | |
| SCHEMBL1543519 | 0.79 | HSD11B1 (0.44) | HSD11B1KDM4E | |
| SCHEMBL18231651 | 0.77 | HSD11B1 (0.39) | HSD11B1LMNA | |
| SCHEMBL25840969 | 0.77 | RET (0.34) | — | |
| SCHEMBL15076640 | 0.77 | RET (0.32) | — | |
| SCHEMBL20084013 | 0.77 | HSD11B1 (0.32) | HSD11B1 | |
| SCHEMBL20315421 | 0.76 | HSD11B1 (0.41) | HSD11B1 | |
| SCHEMBL18855653 | 0.76 | HSD11B1 (0.41) | HSD11B1LMNA | |
| SCHEMBL23555650 | 0.75 | OPRD1 (0.39) | HSD11B1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11168090-B2 | Substituted pyrazolo[1,5-a]pyrazines as RET kinase inhibitors | ARRAY BIOPHARMA INC. (US) | 2021-11-09 | — | — | US | disclosed |
| US-20200055860-A1 | SUBSTITUTED PYRAZOLO[1,5-A]PYRAZINE COMPOUNDS AS RET KINASE INHIBITORS | ARRAY BIOPHARMA INC | 2020-02-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200055860-A1 | SUBSTITUTED PYRAZOLO[1,5-A]PYRAZINE COMPOUNDS AS RET KINASE INHIBITORS | RET, BRAF, ROR1 | HSD11B1 2467/4885KDM4E 955/4885LMNA 2693/4885 |
| US-11168090-B2 | Substituted pyrazolo[1,5-a]pyrazines as RET kinase inhibitors | RET, BRAF, ROR1 | HSD11B1 2374/4885KDM4E 936/4885LMNA 2727/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.